At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 enrolled
Drug / intervention
Dulaglutide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine
In Brief
A Phase 3 clinical trial evaluating Dulaglutide, Placebo, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 300 participants across 40 sites in 7 countries.
Detailed Summary
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCzechia, Hungary, Italy, Puerto Rico, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedJun 2014
Primary CompletionOct 2015
TodayJul 2026
First PostedJun 2, 2014
Enrollment StartMay 1, 2014
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.1 years ago
Interventions
Dulaglutidedrug
Administered SQ
Placebodrug
Administered SQ
Insulin Glarginedrug
Administered SQ
Metformindrug
Administered orally